WELNOX INJECTION

(DL-Acetylmethionine, L-Carnitine hydrochloride, Vitamin E, Cyanocobalamin)

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE VETERINARY MEDICINAL PRODUCT

WELNOX INJECTION.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:
DL-Acetylmethionine……..200 mg
L-Carnitine hydrochloride……61.3mg eq. to L-Carnitine 50mg
Alpha-tocopherol acetate…..32.9mg eq. to alpha-tocopherol 30mg
Cyanocobalamin……0.2 mg

3. PHARMACEUTICAL FORM

Solution for Injection.

4. CLINICAL INFORMATION

4.1. Target species

Cattle, Sheep & Horse.

4.2. Indications for use specifying the target species

Welnox Injection is indicated in cattle, horses and sheep for nutritional support and is to be administered as an adjunct to standard therapy in animals suffering from toxic and metabolic disorders, in conditions of reduced hepatic functionality, in animals facing heavy and protracted physical stimulus and for the transition cow or for pregnant ewes, and mares.

- Alterations in milk quality or quantity
- Anorexia, dysorexia
- Convalescence, postoperative course
- Dietary imbalance and deficiencies
- Poor performance
- Physical fatigue and debilitation
- Stress management

4.3. Contraindications

None.

4.4. Special warnings for each target species

None.

4.5. Special precautions for use

Special precautions for safe use in the target species:

Observe normal aseptic procedures

Special precautions to be taken by the person administering the product to animals:

Not relevant.

4.6. Adverse reactions (frequency and seriousness)

None known.

4.7. Use during pregnancy and lactation or lay

It can be used during pregnancy and breastfeeding

4.8. Interaction with other veterinary medicinal products and other forms of interaction

No notes.

4.9. Dosage and administration route

For intramuscular use.

Cattle, horses: 5 ml/100kg Body weight.
Calves, sheep, foals: 0.5-1 ml/10 kg Body weight.

Administer once daily for at least 3-5 days.

4.10. Overdose (symptoms, emergency procedures, antidotes), if necessary

Data not available.

4.11. Restrictions and special conditions of use, including restrictions on the use of antimicrobial and antiparasitic veterinary drugs, in order to reduce the risk of resistance development

Medication administered under the control or supervision of the veterinarian

4.12. Withdrawal period:

Cattle, sheep
Meat and offal: zero days.
Milk: zero hours.

Horse: Not Applicable

5. PHARMACOLOGICAL PROPERTIES

ATCVet Code: **QA11JC**

5.1. Pharmacodynamics properties

The veterinary medicinal product is an injectable combination of N-acetyl-DL-methionine (water-soluble acetylated methionine), L-carnitine, dl-alpha-tocopherol (vitamin E) and cyanocobalamin (vitamin B12), four active ingredients that intervene in the metabolic mechanisms involved in the processes of detoxification, transport and use of fatty acids for energy purposes.

The veterinary medicinal product is therefore indicated in the supportive therapy of dysfunctions and metabolic disorders affecting various organs and systems such as the liver, heart, striated muscle, vascular endothelia and immune system.

5.2. Pharmacokinetic information

Once absorbed, N-acetyl-DL-methionine releases the amino acid as such. The resulting sulfate is excreted in the urine as sulfanic acid.

Cyanocobalamin (vitamin B12) binds to specific plasma proteins and diffuses rapidly into all tissues, particularly the liver, where it is stored. Any excess is excreted mainly by the kidneys.

The passage of L-carnitine from the blood to the tissues occurs through an active transport mechanism through cell membranes. It is concentrated mainly in tissues with high oxidative capacity of fatty acids: myocardium, skeletal muscle and liver. L-carnitine is not metabolized except for a small part that is esterified.

Elimination occurs via the kidneys and is directly proportional to blood levels.

Dl-alpha-tocopherol (vitamin E) is transported in the circulatory system by means of γ-lipoproteins. It is distributed abundantly in all tissues and is stored in the liver, where it is partly metabolized. Excretion occurs mainly via the bile, while a minimal part is excreted in the urine.

6. PHARMACEUTICAL INFORMATION

6.1. List of excipients

Benzyl Alcohol
Polyoxyethylene glycol ricinoleate
Sodium hydroxide
Water for injections

6.2. Incompatibilities

In the absence of compatibility studies, this veterinary medicinal product should not be mixed with other veterinary medicinal products.

6.3. Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the container: use immediately in 28 days, do not store.

6.4. Special precautions for storage

Store below 25°C.
Protect from light and moisture.
Keep out of the reach of children.
To be used as directed by the registered veterinary practitioner only.

6.5. Nature and composition of primary conditioning

Cardboard box with glass injection vial (s).
Vial is closed with a bromobutyl rubber stopper and sealed with an aluminum flip off seal.
Pack sizes: 100ml

SPECIAL PRECAUTIONS FOR THE DISPOSAL OF WASTE MATERIALS
UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS

Any unused veterinary medicinal products or waste materials derived from such medicinal products should be disposed of in accordance with local requirements and placed in appropriate collection and disposal systems for unused or expired medicinal products.

7. MARKETING AUTHORISATION HOLDER

Nawan Laboratories (Pvt.) Ltd.
Plots No. 136-138, Sector-15,
Korangi Industrial Area, Karachi-74900, Pakistan.

8. MARKETING AUTHORISATION NUMBER

Reg. No.: 128432

9. DATE OF FIRST AUTHORISATION

Date of Reg.: 03-07-2025

10. DATE OF REVISION OF THE TEXT

01-08-2025

MANUFACTURED BY:

NAWAN LABORATORIES (PVT) LTD. | 136, Sector 15, Korangi Industrial Area, Karachi-74900, Pakistan.